- Home
- OTLK vs IRAB Comparison
OTLK vs IRAB Comparison
Compare OTLK & IRAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OTLK | IRAB |
|---|---|---|
| Founded | 2010 | 2025 |
| Country | United States | United Arab Emirates |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.6M | 227.9M |
| IPO Year | 2016 | 2025 |
Fundamental Metrics
Financial Performance| Metric | OTLK | IRAB |
|---|---|---|
| Price | $0.57 | $10.15 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.03 | N/A |
| AVG Volume (30 Days) | ★ 3.4M | 64.7K |
| Earning Date | 08-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,146,123.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6,355.64 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $9.82 |
| 52 Week High | $2.54 | $10.15 |
Technical Indicators
Market Signals| Indicator | OTLK | IRAB |
|---|---|---|
| Relative Strength Index (RSI) | 31.66 | 62.36 |
| Support Level | $0.50 | $9.92 |
| Resistance Level | $0.72 | N/A |
| Average True Range (ATR) | 0.04 | 0.02 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.06 | 100.00 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About IRAB Iris Acquisition Corp II Class A Ordinary Shares
Iris Acquisition Corp II is a blank check company.